FIG. 7.
A neutralizing CD18 MAb inhibits GBS-induced TNF-α release. Newborn or adult blood was preincubated for 1 h with either a control murine IgG1 MAb to an unrelated antigen (antitrinitrophenol) or a neutralizing murine IgG1 MAb to CD18 before addition of L-GBS type III COH-1 (104 bacteria/ml). TNF-α release was measured at 5 h by ELISA and is expressed as a percentage of control. Data represent the means ± standard errors of the means (n = 2 to 4). Differences between control samples and those containing 225 μg of CD18 MAb/ml were significant (P < 0.05).